Evidence map›Paper›PMID 31021700›Full record

ArticleHuman vaccines & immunotherapeutics2019

In vitro characterization and preclinical immunogenicity of Typhax, a typhoid fever protein capsular matrix vaccine candidate.

Thomas J Griffin, Ann Thanawastien, Robert T Cartee, John J Mekalanos, Kevin P Killeen

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Vaccines for enteric diseases.Human vaccines & immunotherapeutics · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Thomas J Griffina Matrivax Research & Development Corporation , Boston , MA , USA.ORCID 0000-0002-2814-4183
Ann Thanawastiena Matrivax Research & Development Corporation , Boston , MA , USA.
Robert T Carteea Matrivax Research & Development Corporation , Boston , MA , USA.
John J Mekalanosb Department of Microbiology and Immunobiology , Harvard Medical School , Boston , MA , USA.
Kevin P Killeena Matrivax Research & Development Corporation , Boston , MA , USA.
Harvard University · US

Funding

Genetic analysis of toxinogenesis of Vibrio choleraeR37AI018045 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI John Joseph Mekalanos · 1989 to 2026
$12.8M
NIAID NIH HHS R37 AI018045
6 · The paper itself

Abstract

Typhax is an investigational typhoid fever vaccine candidate that was GMP manufactured applying Protein Capsular Matrix Vaccine (PCMV) technology. It consists of Vi polysaccharide antigen, derived from

Indexed as

Immunogenicity, VaccineAnimalsAntibodies, BacterialFemaleImmunoglobulin GMacaca mulattaMiceMice, Inbred BALB CPolysaccharides, BacterialRabbitsSalmonella typhiSeroconversionTyphoid FeverTyphoid-Paratyphoid VaccinesVaccines, ConjugateAntibodies, BacterialImmunoglobulin GPolysaccharides, BacterialTyphoid-Paratyphoid VaccinesVaccines, ConjugateProtein capsular matrix vaccine (PCMV)Typhoid feverVivirtual polysaccharide conjugate

Identifiers

PMID31021700
PMCPMC6663131
OpenAlexW2941083248

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.